obinutuzumab + fludarabine + cyclophosphamide

**obinutuzumab + fludarabine + cyclophosphamide** is a combination regimen used primarily for the treatment of chronic lymphocytic leukemia (CLL) in fit, previously untreated patients. Obinutuzumab is a glycoengineered, type II, humanized monoclonal antibody targeting CD20 on B cells, designed to enhance direct cell death and antibody-dependent cellular cytotoxicity (ADCC) while reducing complement-dependent cytotoxicity (CDC). Fludarabine and cyclophosphamide are antineoplastic small molecules: fludarabine is a purine analog that interferes with DNA synthesis, and cyclophosphamide is an alkylating agent causing DNA crosslinking and cell death. The combination, sometimes abbreviated as G-FC, is administered in 28-day cycles, with obinutuzumab intravenous infusions and standard dosing for fludarabine and cyclophosphamide. Clinical trials show that G-FC achieves high rates of overall and complete response in CLL and is a promising frontline option[1][3][5][7].

Other names

G-FC